VAL489 + VAL489 matching placebo

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pediatric Hypertension With or Without CKD

Conditions

Pediatric Hypertension With or Without CKD

Trial Timeline

Nov 8, 2012 → Jan 24, 2017

NCT ID

NCT01617681

About VAL489 + VAL489 matching placebo

VAL489 + VAL489 matching placebo is a phase 3 stage product being developed by Novartis for Pediatric Hypertension With or Without CKD. The current trial status is completed. This product is registered under clinical trial identifier NCT01617681. Target conditions include Pediatric Hypertension With or Without CKD.

What happened to similar drugs?

3 of 18 similar drugs in Pediatric Hypertension With or Without CKD were approved

Approved (3) Terminated (0) Active (15)

✅Boosted AtazanavirBristol Myers SquibbApproved

✅Atazanavir + RitonavirBristol Myers SquibbApproved

✅IgPro10CSLApproved

🔄candsartan cilexetilAstraZenecaPhase 3

🔄basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3

🔄Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3

🔄EtanerceptAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01617681	Phase 3	Completed	Nov 8, 2012	Jan 24, 2017	Pediatric Hypertension With or Without CKD

Competing Products

20 competing products in Pediatric Hypertension With or Without CKD

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab	Eli Lilly	Phase 1	29
erlotinib + etoposide	Astellas Pharma	Phase 2	27
Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine	Sun Pharmaceutical	Phase 1	33
Perampanel Oral Suspension + Perampanel Tablet	Eisai	Phase 2	42
Eribulin Mesylate	Eisai	Phase 1	29
Decitabine + Decitabine	Eisai	Phase 2	27
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily	Sumitomo Pharma	Phase 1	29
Remimazolam Tosilate for injection + Propofol Injection	Jiangsu Hengrui Medicine	Phase 2/3	45
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid	AstraZeneca	Phase 2/3	38
candsartan cilexetil	AstraZeneca	Phase 3	40
Durvalumab / Tremelimumab Combination Therapy	AstraZeneca	Phase 1/2	36
Rotavirus Vaccine	Merck	Pre-clinical	18
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids	Novartis	Phase 3	40
LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696	Novartis	Phase 2/3	38
Everolimus	Novartis	Phase 2	35
Corticosteroids + Cyclosporine + mycophenolate mofetil	Roche	Phase 2	27
Entecavir + Lamivudine + Pegylated Interferon Alfa-2A	Roche	Phase 3	40
Blinatumomab for Injection	Amgen	Phase 1	25
Etanercept	Amgen	Phase 3	40
Denosumab	Amgen	Phase 3	40